Skip to main content
S&P 5007,636.36-0.48%DOW52,380.66-0.77%NASDAQ26,253.34-0.64%BTC$78,136.00-0.80%ETH$2,465.32-1.24%GOLD$4,444.30-0.37%OIL$96.58+0.55%
Smart Investors Daily
CY

NASDAQ · CYDY

CytoDyn Inc.

Healthcare · Biotechnology

$0.20

Up+$0.00 (+0.44%)

Updated Sep 10, 2026, 8:39 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
408.94M
P/E ratio
-19.25
Dividend yield
0.00%
52-week range
— – —
Volume
574.32K
Avg. volume
1.9M

Price performance

CYDY price history

1M range · 0 trading sessions · Daily adjusted prices

CYDY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest CYDY news

The latest Smart Investors Daily articles mentioning CYDY.

Stock researchCompany · Overview

CYDY research

Overview

Company profile and research snapshot.

Company profile

CYTODYN INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CYDY recent ratings
DateFirmRatingTarget
Jul 6, 2020HC Wainwright & Co.Neutral—
Apr 28, 2020HC Wainwright & Co.Buy—
Apr 3, 2020H.C. WainwrightBuy—
Dec 19, 2019H.C. WainwrightBuy—
Sep 16, 2019HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab

VANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has closed on a financing of $16.5 million in gross proceeds, with Paulson Investment

Yahoo · Jan 27, 2026

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that a compassionate benefactor has formally committed funding to support the Company’s Expande

globenewswire.com · Dec 1, 2025

CytoDyn Announces Resolution of Class Action Lawsuit

VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC), today announced that it has reached an agreement in principle to resolve the previously disclosed securities class action lawsuit that was initially filed in March 2021 against the Company and certain former officers. The case is pending in the United States District Court for the Western District of Washington and is titled Courter et al. v. CytoDyn Inc. et al.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By